TNF inhibitors in Rheumatoid Arthritis: is dose reduction safe and effective for all?

In this blog for health professionals, Professor Paul Bowness, Consultant Rheumatologist in Oxford UK, discusses the implications of the latest Cochrane review from Lisa Verhoef and colleagues from the Netherlands addressing down-titration and discontinuation of Tumour Necrosis Factor inhibitor (TNFi) therapies (also known as anti-TNF agents or TNF-blockers) in Rheumatoid Arthritis.

This is an important topic because large numbers of patients with Rheumatoid Arthritis (RA) (as well other inflammatory arthritides and skin and bowel diseases) are treated with these drugs.  They show good efficacy but are not curative and it has widely been believed that the underlying inflammatory conditions will flare if therapy is discontinued.

The current treatment paradigm for RA (with good supporting evidence) is that early and effective suppression of inflammation leads to greatly reduced long term joint damage (usually assessed radiologically) and preserves function and quality of life.  This suppression is usually achieved by “treat to target” strategies involving combinations of standard disease modifying drugs (usually with methotrexate the “anchor” drug) with targeted often local corticosteroid therapy.

In the UK tumour necrosis factor inhibitors (TNFi) and other biologic therapies are currently NICE-approved for resistant disease with persistent high DAS (disease activity) scores.  Once someone has commenced TNFi therapy and responded there has been relatively little good quality evidence available to guide subsequent treatment decisions.  Patients are frequently keen to discontinue their methotrexate for example because of concerns about side effects.

Cochrane Review may lead to change in practice

This review may lead to widespread change in practice as it provides hard evidence to support a different strategy – that of TNFi dose reduction.

The review includes 14 studies (almost all randomized controlled trials) comprising over 3,000 patients.  Broadly they find that TNFi dose reduction (or increased dosage interval) in RA patients with low disease activity is associated with relatively good outcomes.  By contrast, they find evidence that discontinuation of TNFi therapy leads to adverse outcomes.

TNFi dose reduction for RA patients in remission is thus a viable option in clinical practice and could be both cost-saving and safe and convenient for patients.

Cautions to consider

There are a number of caveats/cautions to consider.  The vast majority of evidence assessed is for the two most widely used agents (at least in our unit) adalimumab and etanercept.  It is likely but unproven that other agents could be similarly reduced. Secondly it will be key to establish the role of methrotexate and other standard DMARD drugs in maintaining remission/low disease activity if TNFi reduction is contemplated.  Thirdly it will be critical not to reduce therapy in patients who feel better but still have active disease without clinically obvious inflammation.

Where does this leave us?

Therefore, in my opinion, we are not ready to adopt such a policy for all patients and TNFi dose reduction in RA should be guided by robust disease activity assessment perhaps in addition to DAS28 CRP and other currently validated tools.  In this respect there is considerable interest in biomarkers that might assist clinical decision making, including ultrasound, gene expression and biochemical markers (or panels of markers) in blood or urine.

In practical terms this suggests that many patients will be reassured that dose reduction is unlikely to lead to disease flare. Rheumatology units could therefore consider TNFi dose reduction strategies for RA patients in remission, whilst maintaining ‘treat to target’ strategy, actively auditing outcomes and contributing to the search for informative biomarkers.

Join in the conversation on Twitter with @CochraneUK @CochraneMSK or leave a comment on the blog.

Links:

Verhoef  LM, van den Bemt  BJF, van der Maas  A, Vriezekolk  JE, Hulscher  ME, van den Hoogen  FHJ, Jacobs  WCH, van Herwaarden  N, den Broeder  AA. Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database of Systematic Reviews 2019, Issue 5. Art. No.: CD010455. DOI: 10.1002/14651858.CD010455.pub3

Dr. Bowness reports grants from Research support from GSK, grants from Research support from Regeneron, grants from Research support from Cellgene, grants from Speaker fee from Pfizer,  outside the submitted work.

 


Paul Bowness

About Paul Bowness

view all posts

Paul Bowness is a Consultant Rheumatologist at the Nuffield Orthopaedic Centre (since 1999) and Professor of Experimental Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal science (NDORMS), Oxford University. He trained at Cambridge University and then undertook postgraduate training in London. He studied under Andrew McMichael and received a DPhil (PhD) in Immunology from Oxford University in 1993. His principle research interests are in the immunology of Spondyloarthritis. He has published over 70 peer-reviewed articles in major scientific journals and has written reviews and chapters in textbooks including in the Oxford Textbook of Medicine. He was elected to ASAS in 2009 and was co-president of the International Congress of the Spondyloarthropathies for 2012.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

UA-49496932-1